期刊文献+

三种微颗粒水平在糖尿病血管病变中的意义 被引量:3

Significance of three kinds of microparticle levels in diabetic angiopathy
原文传递
导出
摘要 目的 分析糖尿病患者微颗粒(包括血小板微颗粒、内皮细胞微颗粒以及组织因子阳性微颗粒)水平,探讨微颗粒水平与糖尿病并发症的相关性.方法 流式细胞仪检测106例糖尿病患者和50例健康志愿者血浆中血小板微颗粒、内皮细胞微颗粒和组织因子阳性微颗粒水平,并比较糖尿病血管病变各组间微颗粒的变化.结果 糖尿病组血小板微颗粒和组织因子阳性微颗粒水平与对照组比较无明显差异(23.09±15.66对38.55±28.56,83.82±82.61对89.06±82.75,均P〉0.05),而内皮细胞微颗粒水平在糖尿病组明显高于对照组(164.20±128.88对63.81±40.84,P〈0.05),合并有血管病变者其内皮细胞微颗粒水平又高于单纯糖尿病组(184.12±152.77、188.21±149.55对138.53±99.87,P〈0.05).结论 内皮细胞功能异常是糖尿病患者,尤其合并有血管病变患者内皮细胞微颗粒升高的原因;内皮细胞微颗粒水平可以用来评价糖尿病患者血管内皮细胞的功能状态和疾病的进展的指标之一. Objective To investigate the levels of mieropartieles originated from platelet (PMP),endothelium (EMP),and tissue factor-bearing microparticles (TF+ MP) in diabetes mellitus and to analyze its relationship with diabetic angiopathy.Methods PMP,EMP or TF+ MP were measured in 106 cases of diabetes mellitus and 50 controls by flow eytometry.The differences of EMP between groups of diabetic macrovascular disease and diabetic microvascular disease were determined.Results The levels of EMP in diabetic patients were higher than that in the control(164.20±128.88 vs 63.81±40.84,P〈0.05).Diabetic cases with complication showed higher expression level of EMP than those without complications(184.12±152.77,188.21±149.55 vs 138.53±99.87,both P〈0.05).However,no distinct increase was observed in PMP and TF+ MP level in diabetes groups compared with control group.Conclusions Endothelial dysfunction,may contribute to the increased level of EMP in patients with diabetes,especially those complicated with vascular diseases.EMP level may be used to evaluate the status of endothelial function and the development of diabetic angiopathy.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2010年第6期465-467,共3页 Chinese Journal of Endocrinology and Metabolism
关键词 糖尿病 血管病变 微颗粒 内皮细胞功能异常 Diabetes mellitus Angiopathy Microparticles Endothelial dysfunction
  • 相关文献

参考文献14

  • 1Heijnen HF,Schiel AE,Fijnheer R,et al.Activated platelets release two types of membrane vesicles:mierovesicles by surface shedding and exesomes derived from exocytosis of multivesieular bodies and αgranules.Blood,1999,94:3791-3799.
  • 2Combes V,Simon AC,Gran GE,et al.In vitro generation of endothelial microparticles and possible prothrombetic activity in patients with lupus anticoagulant.J Clin Invest,1999,104:93-102.
  • 3Simak J,Geldennan MP,Yu H,et al.Circulating endothelial microparticles in acute ischemic stroke:a link to severity,lesion volume and outcome.J Thromb Haemost,2006,4:1296-1302.
  • 4Zwaal RF,Schroit AJ.Pathophysiologie implications of membrane phospholipid asymmetry in blood cells.Blood,1997,89:1121-1132.
  • 5Lentz BR.Exposure of platelet membrane phosphatidylserine regulates blood coagulation.Prog Lipid Res,2003,42:423-438.
  • 6Calles-Escandon J,Ballor Cipolla M.Diabetes and endothelial dysfunction a clinical perpective.Endor Rev,2001,22:36-52.
  • 7Nieuwland R,Berckmans BJ,McGregor S,et al.Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.Blood,2000,95:930-935.
  • 8Hughes M,Hayward CP,Warkentin TE,et al.Morphological analysis of microparticle generation in heparin-induced thrombocytopenia.Blood.2000,96:188-194.
  • 9王振义 李家增 阮长耿 等主编.血栓与止血[A]..基础理论与临床 第2版[C].上海:上海科学技术出版社,1996.424.
  • 10Lusis AJ.Athereselerosis.Nature,2000,407:233-241.

共引文献6

同被引文献29

  • 1Chakroun T,Abdelkefi S,Bouslama M,et al.Platelet-leukocyte aggregates as a marker for platelet activation in platelet concentrates.Transfus Clin Biol,2008,15:148-153.
  • 2Ray MJ,Waiters DL,Bett JN,et al.Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab.Int J Cardiol,2005,101:249-255.
  • 3My(s)liwiec M,Balcerska A,Zorena K,et al.The role of vascular endothelial growth factor,tumor necrosis factor alpha and interleukin-6in pathogenesis of diabetic retinopathy.Diabetes Res Clin Pract,2008,79:141-146.
  • 4Tsunoda K,Arita M,Yukawa M,et al.Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in type 2 diabetic patients.J Diabetes Complications,2005,19:123-127.
  • 5Sarma J,Laan CA,Alam S,et al.Increased platelet binding to circulating monocytes in acute coronary syndromes.Circulation,2002,105:2166-2171.
  • 6Gurbel PA,Galbut B,Bliden KP,et al.Effect of eptifibatide for acute coronary syndromes:rapid versus late administration-therapeutic yield on platelets(The EARLY Platelet substudy).J Thromb Thrombolysis,2002,14:213-219.
  • 7RuefJ,Kuehnl P,Meinertz T,et al.The complement factor properdin induces formation of platelet-leukocyte aggregates via leukocyte activation.Platelets,2008,19:359-364.
  • 8Shoji T,Koyama H,Fukumoto S,et al.Platelet-monocyte aggregates are independently associated with occurrence of carotid plaques in type 2diabetic patients.J Atheroscler Thromb,2005,12:344-352.
  • 9Kang ES,Kim HJ,Ahn CW,et al.Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes.Diabetes Res Clin Pract,2005,69:151-159.
  • 10Joussen AM,Poulaki V,Le ML,et al.A central role for inflammation in the pathogenesis of diabetic retinopathy.FASEB J,2004,18:1450-1452.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部